Home>Topics>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. UPDATE 1- GSK , NewLink working to bring Ebola vaccines online - WHO

    Headlines

    Wed, 1 Oct 2014

    GENEVA, Oct 1 (Reuters) - Both GlaxoSmithKline and NewLink Genetics are working to boost their capacity to make Ebola vaccines, with a goal of a "very significant increase in scale during the first half of 2015", the World Health Organization said on Wednesday.

  2. GSK , NewLink working to bring Ebola vaccines online - WHO

    Headlines

    Wed, 1 Oct 2014

    GENEVA, Oct 1 (Reuters) - Both GlaxoSmithKline and NewLink are working to boost their capacity to make Ebola vaccines, with a goal of a "very significant increase in scale during the first half of 2015", the World Health Organization (WHO) said on Wednesday.

  3. GlaxoSmithKline Needs Healthy Doses Of Good News Post China Scandal

    Headlines

    Mon, 29 Sep 2014

    By Wall Street Playbook : Last week, drug giant GlaxoSmithKline (NYSE: GSK ) was found guilty on bribery charges and has been ..... company rules. In a statement, the company said: " GSK Plc sincerely apologizes to the Chinese patients

  4. 45% of Tafinlar-treated melanoma patients still surviving

    Headlines

    Mon, 29 Sep 2014

    At the ESMO Congress in Madrid, Spain, GlaxoSmithKline ( GSK -0.6% ) presented overall survival data from a ..... months versus 15.6 months in the dacarbazine group. GSK Oncology Chief Dr. Paolo Paoletti says, "We are

  5. Cobimetinib Combo Results are Positive, but Melanoma Landscape Is Becoming More Challenging

    Commentary

    Mon, 29 Sep 2014

    expected and similar to Novartis’ competing Mekinist and Tafinlar combination, which was recently acquired from GlaxoSmithKline and targets the same patient population, we are maintaining our $2.10 fair value estimate and no-moat, stable

  6. Roche, GSK cancer pill combos look similar in showdown

    Headlines

    Mon, 29 Sep 2014

    MADRID, Sept 29 (Reuters) - Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline have yielded similar results in separate clinical trials, leaving doctors with little to choose between the two regimens.

  7. Why Is Merck Running To 52-Week Highs Again? ESMO Conference This Weekend

    Headlines

    Thu, 25 Sep 2014

    up over 20% YTD and outperforming its key rivals Pfizer (NYSE: PFE ), Johnson & Johnson (NYSE: JNJ ), GlaxoSmithKline (NYSE: GSK ), Novartis (NYSE: NVS ), & Bristol-Myers Squibb (NYSE: BMY ) (Figure 1.). Merck is up 20% YTD

  8. Thermo Fisher to develop companion diagnostics for GSK and PFE

    Headlines

    Thu, 25 Sep 2014

    Thermo Fisher Scientific (NYSE: TMO ) enters into an agreement with GlaxoSmithKline (NYSE: GSK ) and Pfizer (NYSE: PFE ) to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will

  9. Chairman Hampton to Step Down From RBS

    Commentary

    Thu, 25 Sep 2014

    announced on Sept. 25 that its chairman, Sir Phillip Hampton, will step down in 2015 to become the chairman of GlaxoSmithKline . We’re not surprised by Hampton’s impending departure, since he and the bank have long signaled that he

  10. RBS chairman exiting to join GSK

    Headlines

    Thu, 25 Sep 2014

    chairman of RBS since 2009, but he will step down at some point next year, and begin serving on the board at GlaxoSmithKline (NYSE: GSK ) on January 1. He's expected to succeed Christopher Gent as Glaxo's chairman by September 2015. RBS

« Prev12345Next »
Content Partners